SOPHiA GENETICS (SOPH) 2025 Conference May 21, 2025 10:00 AM ET Speaker0 Twenty twenty five RBC Capital Markets Global Healthcare Conference. I'm Connor McNamara, the life science tools and diagnostics analyst at RBC. It's my pleasure to introduce our our next company company, Sofia Genetics. On stage with me is CFO, George Cardoza and head of strategy, I believe IR. More strategy. Okay. Kellen Sanger, welcome, and thank you for being here. Speaker1 Thank you. Thanks. Speaker0 Let's just get started on reha ...

SOPHiA GENETICS (SOPH) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Company Participants Kellen Sanger - Sr. Director, Head of StrategyJurgi Camblong - Co-Founder, CEO & DirectorRoss Muken - PresidentGeorge Cardoza - EVP & CFOSubbu Nambi - Managing DirectorVidyun Bais - Equity Research - Vice President Conference Call Participants William Bonello - Senior Research AnalystConor McNamara - Equity Research AnalystNone - AnalystKyle Boucher - Analyst Operator Good morning, ladies and gentlemen, and welcome to ...

Company Performance - SOPHiA GENETICS reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -23.81% [1] - The company posted revenues of $17.78 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.30% and showing an increase from $15.78 million in the same quarter last year [2] - Over the last four quarters, SOPHiA GENETICS has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Market Outlook - SOPHiA GENETICS shares have increased by approximately 2.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of $17.85 million, and for the current fiscal year, it is -$0.80 on revenues of $74.18 million [7] Industry Context - The Medical Info Systems industry, to which SOPHiA GENETICS belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for SOPHiA GENETICS is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $17.8 million, up from $15.8 million in Q1 2024, representing a year-over-year growth of 13% [32] - On a constant currency basis, revenue growth was 15%, with foreign exchange headwinds negatively impacting reported revenue by approximately $0.4 million [32] - Adjusted EBITDA loss improved by 24% year-over-year, reaching $9.8 million in Q1 2025 compared to $12.9 million in Q1 2024 [36] - Adjusted gross margin reached a record high of 75.7%, up from 70.6% in the prior year [34] Business Line Data and Key Metrics Changes - Core genomic customers increased to 490 as of March 31, 2025, up from 463 in the prior year [32] - The company implemented 33 new customers in Q1 2025, compared to an average of 23 per quarter in 2024 [8][32] - Hematology-oncology (HemOnc) volumes grew 34% year-over-year in Q1 2025, with over 180 HemOnc customers globally [21] Market Data and Key Metrics Changes - Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year [9] - UK analysis volume grew over 60% year-over-year, with UK revenue up approximately 80% [20] - North America and Asia Pacific outperformed with 3240% year-over-year volume growth respectively [19] Company Strategy and Development Direction - The company aims to capitalize on new customer signings by expediting implementation times and expanding across those accounts over time [8] - Focus areas for growth in 2025 include the U.S. market, new applications like MSK Access and MSK Impact, and partnerships with biopharma [9][11] - The company is positioned to leverage its scalable cloud-based platform to support medical innovations and drive future growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, citing the increasing demand for data-driven medicine and the company's unique AI capabilities [44] - The company reaffirmed its full-year revenue guidance for 2025 of $70 million to $76 million, representing 10% to 17% growth [38] - Management noted that while Q1 results were strong, they expect the year to be back-half weighted due to the timing of new business coming online [38][94] Other Important Information - The company finished Q1 2025 with approximately $68.5 million in cash and cash equivalents, plus access to an additional $35 million in capital [37] - The company is focused on maintaining operational efficiencies while continuing to invest in high ROI projects [36] Q&A Session Summary Question: Actions taken to accelerate implementation times - Management highlighted that they have scaled up team capabilities, created tooling and automation, and increased headcount in wet lab and field application scientists to speed up the implementation process [48][50] Question: Average contract value increase and enterprise sales - Management confirmed that 58% of customers are using two or more applications, indicating room for expansion. They noted that enterprise sales involve signing for a majority of applications, which is driving the increase in average contract value [55][56] Question: Sustainability of gross margins above 75% - Management acknowledged that while Q1 gross margins were higher than expected due to a favorable mix, they still anticipate year-over-year improvements in gross margins moving forward [66] Question: Biopharma side opportunities and guidance - Management indicated that while they expect the biopharma segment to be flat in 2025, they are seeing good momentum and opportunities in the pipeline, particularly in companion diagnostics and sponsored testing [70] Question: Balance sheet sufficiency for adjusted EBITDA breakeven target - Management confirmed that with over $100 million in available liquidity, they are well-positioned to reach their adjusted EBITDA breakeven target by 2027 [90]

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | Three months ended | March 31, | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Notes | 2025 | 2024 | 5 | Revenue | $ | 17,779 | $ | 15,779 | | Cost of revenue | (5,571) | (5,374) | Gross profit | 12,208 | 10,405 | | | | | Research and development costs | (9,118) | (9,391) | Selling and marketing costs | (7,534) | (6,951) | | | | | General and administrative costs | (11,600) | (12,825) | Other operating inco ...

Company Overview The AI Platform for Precision Medicine May 6, 2025 Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking state ...

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]

BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions world ...

Financial Data and Key Metrics Changes - Total revenue for 2024 was $65.2 million, representing a year-over-year growth of 4% [50] - Adjusted gross margin improved to 72.8%, up 60 basis points from the previous year [55] - Adjusted operating loss for 2024 was $44.8 million, improving by 20% year-over-year [56] - Total cash burn for 2024 was $58 million, up 5% from the previous year [57] Business Line Data and Key Metrics Changes - Clinical revenue grew 23% in the U.S. in 2024, with analysis volume increasing by 26% [16] - The company signed a record 92 new core genomic customers in 2024, with 35 new customers implemented in Q4 alone [13][14] - Hematology was the top-performing application in 2024, followed by Solid Tumors and rare disease applications [29] Market Data and Key Metrics Changes - North America and Asia Pacific saw significant growth, with volume growth of 33% and 40% year-over-year, respectively [27] - Latin America experienced a decline due to the acquisition of a top customer, but the company has since regained this business [28] Company Strategy and Development Direction - The company aims to expedite implementation times for new customers and expand usage across accounts as a key growth driver [12] - Focus on growing new applications, MSK-ACCESS and MSK-IMPACT, which are expected to significantly impact clinical and BioPharma businesses [20][21] - Continued investment in product upgrades and launches, including Enhanced Exomes and improvements to Liquid Biopsy offerings [31][33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the BioPharma sector due to tightened budgets but expressed optimism for recovery [8][76] - The company expects to report full-year revenue between $72 million and $76 million for 2025, representing 10% to 17% growth [59] - Management is confident in achieving adjusted EBITDA breakeven by the end of 2026 [67] Other Important Information - The company analyzed a record 352,000 patients on SOPHiA DDM in 2024, benefiting from a global reach of nearly 800 healthcare institutions [10] - The company has access to an additional $35 million of capital through a financing line with Perceptive Advisors [67] Q&A Session Summary Question: What are you seeing in terms of BioPharma funding and recovery trends? - Management noted that the BioPharma environment has been challenging, but they are seeing improved momentum in the pipeline and activity rates with pharma [75][80] Question: What indicators give you line of sight into customer volumes? - Management highlighted the backlog of signed contracts and the strong expansion of existing accounts as indicators of future customer volumes [87][89] Question: What is embedded in your ASP assumptions for 2025? - Management indicated that while volume growth is expected to be strong, ASPs may be impacted by the loss of certain pharma-linked business, but new products are expected to help pull ASPs back up [100][101]

Group 1 - SOPHiA GENETICS reported a quarterly loss of $0.23 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.24, and an improvement from a loss of $0.37 per share a year ago, indicating an earnings surprise of 4.17% [1] - The company generated revenues of $17.73 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.36% and showing an increase from $17.05 million in the same quarter last year [2] - SOPHiA GENETICS shares have increased by approximately 16.3% since the beginning of the year, contrasting with a decline of 0.5% in the S&P 500 [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $17.5 million, while for the current fiscal year, the estimate is -$0.81 on revenues of $74.96 million [7] - The Zacks Industry Rank places Medical Info Systems in the top 28% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than a factor of 2 to 1 [8]